welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy
study id #: NCT02195999
condition: Muscular Dystrophy, Duchenne
This study seeks to develop and validate non-invasive assessments of cardiac and respiratory muscles with magnetic resonance imaging (MRI) to better predict the natural disease progression of Duchenne muscular dystrophy (DMD) in affected individuals over time, as well as determine whether peripheral skeletal muscle dysfunction can predict cardiopulmonary dysfunction. The central hypothesis is that non-invasive MRI measures of the heart, muscle, and peripheral skeletal muscles can sensitively predict future cardiopulmonary decline.
Magnetic Resonance Imaging (MRI), Pulmonary Function Testing (PFT), Metabolic Exercise Testing using stationary bicycle, Echocardiogram
mechanism of action: No pharmaceutical intervention
last updated: April 01, 2019
start date: December 2013
estimated completion: March 6, 2019
size / enrollment: 9
study description: Magnetic Resonance Imaging (MRI) of the heart and breathing muscles, special breathing tests (called pulmonary function testing), special exercise tests (using a stationary bike), and possibly an echocardiogram (ultrasound of the heart, commonly known as an "echo") will be completed up to 4 times per year for up to 4 years. Most participants will complete testing once or twice each year; however, some participants will be asked to repeat some of the tests twice during each visit.
- Magnetic Resonance (MRI) T2 and Magnetic Resonance Spectroscopy (MRS) [ Time Frame: up to 4 years ]
The MRI T2 and MRS will be used as a noninvasive marker of myocardial damage/inflammation of participants of this study as an early detection for DMD.
- Pulmonary Function Testing (PFT) [ Time Frame: up to 4 years ]
Non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
- Metabolic Exercise Testing (exercise capacity and MVO2) [ Time Frame: up to 4 years ]
With the use of metabolic exercise testing, the aim is to correlate changes in cardiopulmonary function with decline in peripheral skeletal muscle function in individuals with DMD. Metabolic exercise testing includes measuring exercise capacity and maximum oxygen consumption (MVO2).
- Multiple-echo Dixon [ Time Frame: up to 4 years ]
The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure. This method and MRS will also be used for fat fraction determination.
• 5-15 years old at the time of enrollment
• Diagnosed with DMD (as defined by parent project)
• Written parental informed consent (and assent where appropriate) before any study procedures take place
• Contraindication to an MRI examination
• Presence of a secondary condition that impacts muscle function or metabolism, that leads to developmental delay or impaired motor control, or that is not stable
• Participant is unable to comply with study requirements
• Congenital structural abnormality of the heart, repaired or unrepaired
• Clinically contraindicated participation
DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UKWith Duchenne muscular dystrophy (DMD) c...
Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular DystrophyRecent increases in the number and bread...
Targeted re-sequencing emulsion PCR panel for myopathies: Results in 94 casesBackground: Molecular diagnostics in th...
Clinical trial shows some promise for Duchenne muscular dystrophy drugThe results of an international clinical...
New Muscular Dystrophy Clues UncoveredPatients with Duchenne muscular dystroph...
DMD clinical therapies II: P.135 DMD-HUB: expanding clinical trial capacity for Duchenne muscular dystrophy, 1 year ...The need to increase capacity for Duchen...
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...